Type 2 diabetes is a chronic disease that affects millions of people worldwide. It occurs when the body becomes resistant to insulin, which is a hormone that regulates blood sugar levels.
It can lead to a variety of complications such as heart disease, kidney damage, and nerve damage, to name a few. Sanofi, a leading pharmaceutical company, conducted a study that has provided hopeful findings for those living with type 2 diabetes.
The Study
The study conducted by Sanofi has shown that once-daily Toujeo, a long-acting insulin, can help reduce the number of hypoglycemic events in patients with type 2 diabetes.
Hypoglycemia occurs when blood sugar levels drop too low, which can lead to seizures or other serious complications.
The Findings
The study involved 920 patients with type 2 diabetes, and they were assigned randomly to receive either Toujeo or insulin glargine U100, which is another long-acting insulin.
After six months, the patients who received Toujeo had significantly fewer hypoglycemic events compared to those who received insulin glargine U100.
Related Article
Sanofi study reveals potential for positive outcomes in type 2 diabetes
Furthermore, those who received Toujeo also saw a reduction in their HbA1c levels, which is a marker of blood sugar control over the past few months.
The reduction in HbA1c levels was similar in patients who received either Toujeo or insulin glargine U100, indicating that both treatments were equally effective in controlling blood sugar levels.
Implications
The findings of this study have important implications for those living with type 2 diabetes. Hypoglycemic events can be life-threatening, and anything that can reduce their occurrence is welcome news.
Additionally, the reduction in HbA1c levels indicates that Toujeo is an effective treatment for controlling blood sugar levels in patients with type 2 diabetes.
Conclusion
The results of the Sanofi study are very promising for those with type 2 diabetes. The reduction in hypoglycemic events and the control of blood sugar levels are valuable health benefits for people seeking an improvement in their quality of life.
Sanofi has made significant progress in finding effective treatments for those with type 2 diabetes and future research is essential in continuing to move forward.
